Overview

Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients

Status:
Unknown status
Trial end date:
2020-12-15
Target enrollment:
Participant gender:
Summary
This study will evaluate the use of Heated Intraperitoneal Chemotherapy (HIPEC) for primary treatment of ovarian cancer at the time of surgical debulking, to assess if intravenous (IV) chemotherapy can be started within 42 days of HIPEC and cytoreduction. All patients will receive cytoreductive surgery followed by a one-time closed HIPEC with cisplatin at 41-43 degrees Celsius for 90 minutes in the operating room. This is followed by 6 cycles of intravenous carboplatin and paclitaxel on an outpatient basis.
Phase:
Phase 2
Details
Lead Sponsor:
Andrea Jewell
Collaborator:
University of Kansas Medical Center
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Paclitaxel